2922-45-4

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Pyridinesulfonamide is used as a building block for the synthesis of various pharmaceuticals, particularly for the development of potential therapeutic agents targeting a wide range of diseases. Its unique structure and properties make it a valuable component in the creation of novel drugs.
Used in Antibacterial Applications:
3-Pyridinesulfonamide is utilized as an antibacterial agent, demonstrating effectiveness against various bacterial strains. Its sulfonamide group contributes to its ability to inhibit bacterial growth, making it a promising candidate for the development of new antimicrobial drugs.
Used in Antifungal Applications:
In the field of antifungal research, 3-Pyridinesulfonamide is employed as an antifungal agent, showing potential in combating fungal infections. Its presence can disrupt the growth and proliferation of fungi, offering a valuable tool in the treatment of various fungal diseases.
Used in Anti-inflammatory Applications:
3-Pyridinesulfonamide is also used as an anti-inflammatory agent, exhibiting properties that can help reduce inflammation and alleviate symptoms associated with inflammatory conditions. Its potential use in this area highlights its diverse range of biological activities.
Used in Corrosion Inhibition:
3-Pyridinesulfonamide has been investigated for its potential use as a corrosion inhibitor in metal alloys. Its ability to form protective layers on metal surfaces can help prevent corrosion, making it a valuable additive in various industrial applications, particularly in the manufacturing and maintenance of metal structures and components.

InChI:InChI=1/C5H6N2O2S/c6-10(8,9)5-2-1-3-7-4-5/h1-4H,(H2,6,8,9)

Upstream product

• 16133-25-8 Pyridine-3-sulfonyl chloride 
• 42899-76-3 pyridine-3-sulfonyl chloride hydrochloride 
• 636-73-7 3-pyridinesulfonic acid 
• 60-29-7 diethyl ether 
• 75-09-2 dichloromethane 
• 110-86-1 pyridine 

Downstream Products

• 128924-71-0 C₁₂H₁₀ClN₃O₃S 
• 68498-70-4 pyridine-3-sulfonamide N-oxide 
• 1609109-59-2 C₃₃H₄₁N₅O₅S 
• 1071519-10-2 pyridine-3-sulfonic acid {3-[(1R,2S,7R,8S)-3-(4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}amide 
• 881408-61-3 tert-butyl [2-[3'-(isopropylthio)-4'-[[(3-pyridylsulfonyl)amino]carbonyl]-4-biphenylyl]-ethyl][(2R)-2-phenyl-2-(tetrahydro-2H-pyran-2-yloxy)-ethyl]carbamate 
• 33003-64-4 5-(aminosulfonyl)-2-methylpyridine-N-oxide 

Relevant academic research and scientific papers

Electrochemically generatedN-iodoaminium species as key intermediates for selective methyl sulphonylimination of tertiary amines

Reported herein is a straightforward protocol for approachingN-sulphonylamidinesviaan electricity-driven, iodine-mediated cross dehydrogenative condensation (CDC) between sulphonamides and tertiary amines, which features exclusive N-CH3selectivity for the amine partners. Mechanistic studies indicate that anin situgeneratedN-iodoaminium species serves as the key intermediate.

N-acyl sulfamide FBPase inhibitor, preparation method thereof, drug composition and application

The invention discloses an N-acryl sulfamide FBPase inhibitor of a novel structure, and a preparation method thereof, a drug composition and an application, and particularly relates to an N-acryl sulfamide FBPase inhibitor shown in the formula I, a salt thereof for medicine, a preparation method, a composition comprising one or more compounds, an application of the compound in preparing the FBPase inhibitor or a drug for treating FBPase-related diseases, and an application in preparing a drug for preventing and/or treating diabetes. The formula is shown in the description.

THIAZOLIDINONE COMPOUNDS AND USE THEREOF

A pharmaceutical composition containing a compound of Formula (I) for treating an opioid receptor-associated condition. Also disclosed is a method for treating an opioid receptor-associated condition using such a compound. Further disclosed are two sets of thiazolidinone compounds of formula (I): (i) compounds each having an enantiomeric excess greater than 90% and (ii) compounds each being substituted with deuterium.

SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME

ABSTRACT The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

SULFONYLAMINOCARBONYL DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USES THEREOF

This disclosure is related to a sulfonylaminocarbonyl derivative of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the sulfonylaminocarbonyl derivatives of formula (I) and/or a pharmaceutically acceptable salt thereof, preparation methods thereof, and use thereof in treating FXR and/or TGR5 mediated diseases, including primary biliary cirrhosis, nonalcoholic fatty liver, portal hypertension, bile acid diarrhea and cholestasis, type II diabetes and obesity, etc.

Identification of the first potent, selective and bioavailable PPARα antagonist

The discovery and SAR of a novel series of potent and selective PPARα antagonists are herein described. Exploration of replacements for the labile acyl sulfonamide linker led to a biaryl sulfonamide series of which compound 33 proved to be suitable for further profiling in vivo. Compound 33 demonstrated excellent potency, selectivity against other nuclear hormone receptors, and good pharmacokinetics in mouse.

Identification of a sirtuin 3 inhibitor that displays selectivity over sirtuin 1 and 2

As part of an effort to identify novel selective modulators of sirtuins, we synthesized and tested several isosteres and constrained analogues of nicotinamide. Biological data suggest that compound 2 is selective for Sirt3 over Sirt1 and Sirt2.

Crystal structures of pyridine sulfonamides and sulfonic acids

Despite the widespread occurrence of pyridinesulfonic acid and pyridinesulfonamide functional groups in drugs and pharmaceuticals, and their use as ligands in metal-organic frameworks, a systematic structural study of their hydrogen bonding and molecular packing is lacking. We discuss crystal structures of 2-, 3-, and 4-pyridinesulfonic acids/amides in terms of N +-H???O- hydrogen bonds, N-H???O dimer/catemer synthons, and graph set notations. This model study provides a background for polymorph screening and solid form hunting of pharmacologically active sulfonamides.

PI3 KINASE MODULATORS AND METHODS OF USE

The present invention comprises a new class of compounds capable of modulating the activity of PI3 kinase and, accordingly, useful for treatment of PI3 kinase mediated diseases, including melanomas, carcinomas and other cancer-related conditions. The compounds have a general Formula I wherein each of A1, A2, A3, A4, X, R1 and R2 are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of PI3 kinase mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.

QUINOXALINE COMPOUNDS AND USE THEREOF

The present invention is related to quinoxaline compounds of Formula (I) in particular for the treatment of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.